» Articles » PMID: 17513791

Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-2

Overview
Journal J Immunol
Date 2007 May 22
PMID 17513791
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

Angiopoietins 1 and 2 bind to Tie-2 expressed on endothelial cells and regulate vessel stabilization and angiogenesis. Tie-2(+) monocytes have been shown to be recruited to experimental tumors where they promote tumor angiogenesis. In this study, we show that 20% of CD14(+) human blood monocytes express Tie-2, and that these cells coexpress CD16 (FcgammaRIII) and are predominantly CD34 negative. Ang-2 is up-regulated by endothelial cells in malignant tumors and inflamed tissues, so our finding that Ang-2 is a chemoattractant for human Tie-2(+) monocytes and macrophages, suggests that it may help to recruit and regulate their distribution in such tissues. Ang-2 was also found to markedly inhibit release of the important proinflammatory cytokine, TNF-alpha, by monocytes in vitro. Following extravasation of monocytes, and their differentiation into macrophages, many accumulate in the hypoxic areas of inflamed and malignant tissues. Ang-2 is known to be up-regulated by hypoxia and we show that monocytes and macrophages up-regulate Tie-2 when exposed to hypoxia. Furthermore, hypoxia augmented the inhibitory effect of Ang-2 on the release of the anti-angiogenic cytokine, IL-12 by monocytes. In sum, our data indicate that Ang-2 may recruit Tie-2(+) monocytes to tumors and sites of inflammation, modulate their release of important cytokines and stimulate them to express a proangiogenic phenotype.

Citing Articles

Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy.

Toghraie F, Bayat M, Hosseini M, Ramezani A Cell Oncol (Dordr). 2025; .

PMID: 39998754 DOI: 10.1007/s13402-025-01051-y.


Reversal of Endothelial Cell Anergy by T Cell-Engaging Bispecific Antibodies.

Goncalves M, Warwas K, Meyer M, Schwartz-Albiez R, Bulbuc N, Zornig I Cancers (Basel). 2025; 16(24.

PMID: 39766150 PMC: 11674949. DOI: 10.3390/cancers16244251.


Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.

Ma Y, Sun Y, Guo H, Yang R Front Immunol. 2024; 15:1418131.

PMID: 39606239 PMC: 11599180. DOI: 10.3389/fimmu.2024.1418131.


[Advances on physiology and pathology of subpopulations of macrophages in the lung tissue].

Zhong X, Lyu C, Lai D, Shu Q Zhejiang Da Xue Xue Bao Yi Xue Ban. 2024; 53(5):650-658.

PMID: 39343742 PMC: 11528147. DOI: 10.3724/zdxbyxb-2024-0129.


Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy.

Huang Y, Fan H, Ti H Asian J Pharm Sci. 2024; 19(2):100902.

PMID: 38595331 PMC: 11002556. DOI: 10.1016/j.ajps.2024.100902.